Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV130 bacterial vaccine in moderate to severe COPD
NCT01842360Phase 3Completed
- Sponsor
- Inmunotek
- Start
- May 2013
- Primary completion
- Jul 2019
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MV130 in chronic obstructive pulmonary disease (COPD), sponsored by Inmunotek. Started May 2013; status: completed.
02
Drugs
MV130
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01842360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842360.